Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 382


The endogenous Cell-Fate Factor Dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL Signaling Module.

Chen K, Wu K, Jiao X, Wang L, Ju X, Wang M, Di Sante G, Xu S, Wang Q, Li K, Sun X, Xu C, Li Z, Casimiro MC, Ertel A, Addya S, McCue PA, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG.

Cancer Res. 2015 Mar 13. pii: canres.0611.2014. [Epub ahead of print]


Antibiotics for cancer therapy.

Pestell RG, Rizvanov AA.

Oncotarget. 2015 Feb 20;6(5):2587-8. No abstract available.


Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.

Lamb R, Harrison H, Smith DL, Townsend PA, Jackson T, Ozsvari B, Martinez-Outschoorn UE, Pestell RG, Howell A, Lisanti MP, Sotgia F.

Oncotarget. 2015 Mar 10;6(7):4585-601.


Sirt1-deficient mice have hypogonadotropic hypogonadism due to defective GnRH neuronal migration.

Di Sante G, Wang L, Wang C, Jiao X, Casimiro MC, Chen K, Pestell TG, Yaman I, Di Rocco A, Sun X, Horio Y, Powell MJ, He X, McBurney MW, Pestell RG.

Mol Endocrinol. 2015 Feb;29(2):200-12. doi: 10.1210/me.2014-1228. Epub 2014 Dec 29.


Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.

Di Sante G, Pestell TG, Casimiro MC, Bisetto S, Powell MJ, Lisanti MP, Cordon-Cardo C, Castillo-Martin M, Bonal DM, Debattisti V, Chen K, Wang L, He X, McBurney MW, Pestell RG.

Am J Pathol. 2015 Jan;185(1):266-79. doi: 10.1016/j.ajpath.2014.09.014.


BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion.

Cekanova M, Fernando RI, Siriwardhana N, Sukhthankar M, De la Parra C, Woraratphoka J, Malone C, Ström A, Baek SJ, Wade PA, Saxton AM, Donnell RM, Pestell RG, Dharmawardhane S, Wimalasena J.

Exp Cell Res. 2015 Feb 1;331(1):1-10. doi: 10.1016/j.yexcr.2014.11.016. Epub 2014 Dec 9.


CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.


Caveolin-1 regulates the anti-atherogenic properties of macrophages.

Pavlides S, Gutierrez-Pajares JL, Katiyar S, Jasmin JF, Mercier I, Walters R, Pavlides C, Pestell RG, Lisanti MP, Frank PG.

Cell Tissue Res. 2014 Dec;358(3):821-31. doi: 10.1007/s00441-014-2008-4. Epub 2014 Oct 17.


The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.

Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu CL, Yenugonda V, Kallakury B, Dritschilo A, Lynch J, Schlegel R, Rodriguez O, Pestell RG, Avantaggiati ML, Albanese C.

Oncotarget. 2014 Nov 15;5(21):10678-91.


The potential to target CCL5/CCR5 in breast cancer.

Velasco-Velázquez M, Xolalpa W, Pestell RG.

Expert Opin Ther Targets. 2014 Nov;18(11):1265-75. doi: 10.1517/14728222.2014.949238. Epub 2014 Sep 26.


Acetylation-defective mutant of Pparγ is associated with decreased lipid synthesis in breast cancer cells.

Tian L, Wang C, Hagen FK, Gormley M, Addya S, Soccio R, Casimiro MC, Zhou J, Powell MJ, Xu P, Deng H, Sauve AA, Pestell RG.

Oncotarget. 2014 Sep 15;5(17):7303-15.


miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer.

Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, Pestell RG, Liang L, Yu Z.

Molecules. 2014 May 30;19(6):7122-37. doi: 10.3390/molecules19067122.


The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster.

Jin L, Lim M, Zhao S, Sano Y, Simone BA, Savage JE, Wickstrom E, Camphausen K, Pestell RG, Simone NL.

Breast Cancer Res Treat. 2014 Jul;146(1):41-50. doi: 10.1007/s10549-014-2978-7. Epub 2014 May 27.


MicroRNA-mediated cancer metastasis regulation via heterotypic signals in the microenvironment.

Ma H, Liang C, Wang G, Jia S, Zhao Q, Xiang Z, Li Y, Cho WC, Pestell RG, Liang L, Yu Z.

Curr Pharm Biotechnol. 2014;15(5):455-8.


Cyclin D1 integrates estrogen-mediated DNA damage repair signaling.

Li Z, Chen K, Jiao X, Wang C, Willmarth NE, Casimiro MC, Li W, Ju X, Kim SH, Lisanti MP, Katzenellenbogen JA, Pestell RG.

Cancer Res. 2014 Jul 15;74(14):3959-70. doi: 10.1158/0008-5472.CAN-13-3137. Epub 2014 May 15.


CAPER, a novel regulator of human breast cancer progression.

Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, Hulit J, Gandara R, Wang C, Pestell RG, Lisanti MP, Jasmin JF.

Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.


Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo.

Pestell RG, Yu Z.

Asian J Androl. 2014 Mar-Apr;16(2):268-9. doi: 10.4103/1008-682X.122364.


Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.

Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG.

Expert Opin Investig Drugs. 2014 Mar;23(3):295-304. doi: 10.1517/13543784.2014.867017. Epub 2014 Jan 3. Review.


Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation.

Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, Wang J, Li Z, Addya S, Sorensen PH, Lisanti MP, Quong A, Ertel A, Pestell RG.

Cancer Res. 2014 Feb 1;74(3):829-39. doi: 10.1158/0008-5472.CAN-13-2466. Epub 2013 Dec 12.


Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer.

Yu Z, Wang L, Wang C, Ju X, Wang M, Chen K, Loro E, Li Z, Zhang Y, Wu K, Casimiro MC, Gormley M, Ertel A, Fortina P, Chen Y, Tozeren A, Liu Z, Pestell RG.

Nat Commun. 2013;4:2812. doi: 10.1038/ncomms3812.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk